November 19, 2012

Extinguishing the Fire of Type 1 Diabetes


Kamada is currently innovating ways to apply therapeutic use for AAT in medicine. The pharmaceutical company has shown promise with the use of Glassia for the treatment of type 1 diabetes.

Glassia may halt the progression of diabetes, enable the pancreas beta cells to continue excreting insulin, providing better glucose balance, thereby lowering or even preventing serious future complications of the disease. The drug is currently approved for patients with Alpha-1 Antitrypsin deficiency. Kamada is preparing Glassia for trials to be approved as a drug to treat Type 1 diabetes.

Type 1 diabetes is like a fire in the beta cells. Ultimately the C-peptide levels (aka life in beta cells) depletes to undetectable because the fuel burning the fire is the insulin-producing cells.  In the last century the use of insulin to treat diabetes has had an effect in controlling blood glucose but no response in controlling the autoimmune attack that provokes the disease.

Glassia is different. Most of the patients in the trial reported reduced use of insulin during most of the trial period, and a corresponding reduction in the level of diabetes antibodies, which may indicate a reduction in the autoimmune response in the pancreas.

The conclusion of Phase I/II trial has validated the safety and efficacy of Glassia as a treatment for Type 1 diabetes. The CEO of Kamada¬†, David Tsur, said “This is the first clinical proof that may result in a global breakthrough in the treatment and cure of juvenile diabetes. The quality of the results obtained moves us forward toward further development of the drug.”

Here we stand, just a few years shy of the 100 year anniversary of the discovery of insulin. With the use of AAT repurposed, we may be looking at a new approach for treating Type 1 diabetes in the next 100 years. Thanks for making the journey a little more interesting, Kamada,

Visit Your Diabetes Health for more resources about health.